

1 Performance evaluation of the Xpert MTB/XDR test for the detection of drug  
2 resistance to *Mycobacterium tuberculosis* among people diagnosed with tuberculosis  
3 in South Africa

4

5 Shaheed Vally Omar<sup>a</sup>, Gail Louw<sup>b,c</sup>, Farzana Ismail<sup>a</sup>, Xiaohong Liu<sup>c</sup>, Dumsani  
6 Ngcamu<sup>a</sup>, Thabisile Gwala<sup>a</sup>, Minty van der Meulen<sup>a</sup>, Lavania Joseph<sup>a</sup>

7 <sup>a</sup>Centre for Tuberculosis, National TB Reference Laboratory, National Institute for  
8 Communicable Diseases a division of the National Health Laboratory Service,  
9 Johannesburg, South Africa

10 <sup>b</sup>Cepheid (PTY) LTD, Johannesburg, South Africa

11 <sup>c</sup>Cepheid, Sunnyvale, California, USA

12

13

14 Corresponding author: [shaheedvo@nicd.ac.za](mailto:shaheedvo@nicd.ac.za)

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 **Abstract**

36

37 Background: Tuberculosis (TB) remains a significant public health concern in South  
38 Africa, with high incidence rates and a growing burden of drug-resistant TB. This  
39 study aimed to assess the diagnostic performance of the Xpert MTB/XDR test, a  
40 novel molecular assay, for detecting drug resistance in TB patients using archived  
41 sputum sediments.

42

43 Methods: The study involved a comprehensive analysis of 322 samples collected  
44 from presumptive TB patients between 2016 - 2019 across South Africa, previously  
45 characterized by phenotypic and genotypic methods. The Xpert MTB/XDR test was  
46 evaluated for its ability to detect resistance to isoniazid (INH), ethionamide (ETH),  
47 fluoroquinolones (FLQ), and second-line injectable drugs (SLID) compared to  
48 phenotypic drug susceptibility testing (pDST) and whole-genome sequencing (WGS).  
49 The Xpert MTB/RIF Ultra and G4 tests were performed to determine agreement with  
50 this test for TB detection.

51

52 Findings: The Xpert MTB/XDR test performance showed excellent sensitivity and  
53 specificity for detecting *Mycobacterium tuberculosis* (*M. tuberculosis*), with a  
54 sensitivity of 98.3% and specificity of 100% compared to culture. The sensitivities  
55 using a composite reference standard, pDST and sequencing, were over 90% for  
56 INH, FLQ, AMK, KAN, and CAP resistance, meeting the WHO target product profile  
57 criteria for this class. A lower sensitivity of 65.9% for ETH resistance was observed,  
58 driven by the limited targets covered by the assay.

59

60 Interpretation: The Xpert MTB/XDR test offers a promising solution for the rapid  
61 detection of drug-resistant TB in South Africa. It could significantly enhance TB  
62 control efforts in this setting and contribute to improved patient care and  
63 management.

64

65

66 Keywords: drug-resistant, TB, molecular, XDR, diagnostic

67

68

69

## 70 **Introduction**

71

72 Progress in achieving the 2018 UN High-Level Meeting targets has been  
73 exceptionally poor for multidrug-resistant (MDR)/Rifampicin Resistant (RR)  
74 tuberculosis (TB) with only 55% of the target achieved between 2018-2022 (1). In a  
75 recent commentary on diagnostics for TB, the authors succinctly summarized the  
76 situation as "... if we cannot find TB, we cannot treat TB. And if we cannot treat TB,  
77 we cannot end TB", highlighting the central role of diagnostics to address the gaps  
78 (2).

79

80 Over the past decade, South Africa has made significant progress towards the  
81 prevention and management of TB disease and drug-resistant TB since adopting the  
82 WHO's recommended diagnostic technologies and therapies. South Africa is now  
83 one of six high-burden countries that achieved the 2020 End TB Strategy milestones  
84 of a 20% reduction in TB incidence rates (3) and has sustained this milestone in  
85 2021 (4). It is ranked as one of the WHO's top 30 high-burden countries MDR/RR-TB  
86 (4) and has a disproportionate burden on the African continent, with 32%  
87 (6781/21402) of the laboratory-confirmed cases reported from this country alone (1).

88

89 One of the key elements for meeting the End TB strategy (5), is the recommendation  
90 to use WHO-endorsed rapid molecular tests, such as the Xpert<sup>®</sup> MTB/RIF ("G4")  
91 (Cepheid, Sunnyvale, CA, USA) for the diagnosis of TB and the detection of  
92 rifampicin (RIF) resistance in patients presumptive of TB rather than smear  
93 microscopy (6) and was fully implemented in 2013 with a subsequent transition to  
94 Xpert<sup>®</sup> MTB/RIF Ultra ("Ultra") in 2017.

95

96 Another target set in the WHO End TB Strategy is for all MDR/RR-TB patients to be  
97 tested for fluoroquinolone (FQ) resistance. In 2022, only 50% of all MDR/RR-TB  
98 patients were tested globally (1). The Bruker-Hain GenoType MTBDR*plus* and  
99 GenoType MTBDR*s*/ line probe assays (LPAs) and phenotypic drug susceptibility  
100 test (DST) based where genotypic methods are not available have been  
101 implemented nationally. However, these assays require specialized facilities and it  
102 can take between 1-4 weeks for results to be available (7, 8).

103

104 An important priority highlighted by WHO has been for a TB DST that is fast, with low  
105 technical skill and minimal infrastructure requirements (9). In response, Cepheid  
106 announced the release of the Xpert<sup>®</sup> MTB/XDR test in July 2020, a test capable of  
107 detecting resistance using melt curve analysis by targeting associated mutations to  
108 isoniazid (INH), ethionamide (ETH), fluoroquinolones (FLQ), and second-line  
109 injectable agents (SLID), such as kanamycin (KAN), amikacin (AMK) and  
110 capreomycin (CAP) (10). The WHO have since endorsed the MTB/XDR test as a low  
111 complexity molecular sputum-based reflex test for the detection of resistance to  
112 these drugs in confirmed *M. tuberculosis* positive specimens (6). The test targets  
113 resistance conferring mutations in the *katG* and *fabG1* genes, *ahpC-oxyR* intergenic  
114 region and *inhA* promoter for INH; *inhA* promoter mutations only for ETH resistance;  
115 the *gyrA* and *gyrB* quinolone resistance determining regions (QRDR) for FLQ; and  
116 the *rrs* gene and the *eis* promoter region for SLID. It reports low-level resistance to  
117 INH and FLQ and also calls resistance to select SLID base on mutations detected.

118

119 The main study that assessed the clinical performance of the Xpert MTB/XDR test  
120 was conducted at 2 study sites (South Africa and China), however the data  
121 presented in this manuscript is focused on the South Africa data set only.

122

123 This study aimed to evaluate the performance of the Xpert MTB/XDR test to detect  
124 drug resistance using phenotypic DST and whole genome sequencing (WGS)  
125 restricted to test targets as the reference standard and success rate of the assay  
126 compared to the G4 and Ultra test.

127

## 128 **Materials and Methods**

### 129 **Ethics**

130 The study was conducted at the Centre for Tuberculosis, National TB Reference  
131 Laboratory at the National Institute for Communicable Diseases a division of the  
132 National Health Laboratory Service in Johannesburg, South Africa. Ethical approval  
133 M160667 for this study was obtained from the University of the Witwatersrand,  
134 Johannesburg Human Research Ethics Committee.

135

### 136 **Sample Eligibility Criteria**

137 Archived sputum sediments, prepared from sputum specimens collected between 29  
138 November 2016 to 20 June 2019 from people with presumptive TB, representative of  
139 all nine provinces in South Africa, were used in this study. These samples were  
140 characterized by phenotypic and genotypic methods and stored at -70°C.

141

142 *M. tuberculosis* positive and *M. tuberculosis* negative specimens were included for  
143 evaluation if a minimum volume of 1mL frozen sputum sediment was available for  
144 testing (11). For *M. tuberculosis* positive specimens, documented results for smear  
145 microscopy, positive culture result on the BD BACTEC Mycobacterial Growth  
146 Indicator Tube 960 (MGIT) platform (BD Biosciences, Sparks, MD, USA) and/or  
147 Lowenstein Jensen (LJ) media were required. In addition, pDST results for isoniazid,  
148 ethionamide, amikacin, kanamycin, capreomycin and moxifloxacin/levofloxacin on  
149 the MGIT platform; sequencing results for *katG*, *inhA* promoter, *fabG1*, *oxyR-ahpC*  
150 intergenic region, *gyrA*, *gyrB*, *rrs* and *eis* promoter; and G4 or Ultra test results were  
151 also required.

152

153 For *M. tuberculosis* negative specimens, documented results indicating negative  
154 culture result on MGIT and/or LJ media was required. Specimens that were  
155 previously thawed were excluded from the study.

156

### 157 **Specimen Processing Procedures**

158 Concentrated sediments were prepared from induced or expectorated sputum and  
159 subsequently stored at -70°C. These specimens were assigned a unique de-  
160 identified specimen ID by a third-party individual not actively involved in the study.  
161 Subsequently, the specimens were decontaminated using a commercial  
162 NaLC/NaOH kit, Alphatec NAC-PAC™ Red (Alpha-Tec Systems, Inc, Vancouver,  
163 WA, USA), with a final concentration of 1.5% sodium hydroxide as per manufactures  
164 instruction. Two drops of the sediment were used to prepare a smear for Auramine-  
165 O staining and were graded in accordance with Global Laboratory Initiative  
166 Guidelines (12).

167

168 A 500µL aliquot of the sediment was inoculated into a MGIT tube and incubated at  
169 37°C in the MGIT 960 system (BD Biosciences, Sparks, MD, USA), until the culture  
170 flagged positive or 42 days to a negative result as per the manufacturers instruction.

171 The MGIT positive cultures were confirmed to be MTB complex by antigen testing  
172 (TBCheck, BD, Sparks, USA) and were inspected for contamination by visual  
173 observations, Ziehl Neelsen (ZN) staining and on blood agar prior to performing  
174 pDST.

175

### 176 **Reference method testing (pDST and WGS)**

177 The MGIT 960 platform and BD Epicentre TBeXiST module (BD Biosciences,  
178 Sparks, MD, USA) was used to perform pDST as previously described (13) which  
179 included, INH, ETH, FLQ (moxifloxacin(MXF), levofloxacin (LEV) and ofloxacin  
180 (OFL)) and SLID (AMK, KAN and CAP). Testing was performed for all MTB/XDR  
181 drug targets using the 2018 updated WHO recommended critical concentrations  
182 (14). Whole genome sequencing (WGS) and variant analysis was performed as  
183 previously described (15).

184

### 185 **Specimen testing:**

#### 186 **Xpert MTB/RIF; Xpert MTB/RIF ULTRA and Xpert MTB/XDR test**

187 Sediments were thawed at room temperature prior to testing and were randomly  
188 assigned for processing on either the G4 or Ultra tests using the GeneXpert 6-colour  
189 module system (Cepheid, Sunnyvale, USA). All sediments were tested on the  
190 MTB/XDR test on the GeneXpert 10-colour module system.

191

192 Briefly, a 1,2mL aliquot of sediment was transferred to a 15mL conical screw-cap  
193 tube and the sample reagent (SR) was added at a 1:3 ratio. The SR-sample mix was  
194 homogenized at room temperature by vigorous shaking 10-20 times and incubated  
195 for 10 minutes, followed by vigorous shaking for 10-20 times before further  
196 incubation for 5 minutes. The SR-sample mix was then used to load either the G4 or  
197 Ultra tests and the MTB/XDR test in accordance with the manufacturer's instructions  
198 using the appropriate GeneXpert system. If an "ERROR", "INVALID" or "NO  
199 RESULT" result was obtained by specimen testing, the specimen was re-tested once  
200 if sufficient specimen was available. If the re-test result was also non-determinant,  
201 the specimen was reported as such.

202

### 203 **Discrepant result resolution**

204 Discrepant results were defined as specimens where the MTB/XDR test and either  
205 pDST or sequencing results were not in agreement. These discrepant results were  
206 categorized as either a false positive result, which indicates a positive MTB/XDR test  
207 result with a negative pDST/or sequencing result or a false negative result, which  
208 indicates a negative MTB/XDR test result with a positive pDST/ sequencing result.  
209 Specimens with discrepant results were investigated as follows: a) the specimen was  
210 re-tested on the Xpert MTB/XDR test, if sufficient volume remained; b) the specimen  
211 was tested using either sequencing or pDST that detected the targets that were not  
212 in agreement; c) standard of care data associated with the specimen were reviewed  
213 to determine the absence or presence of target mutations associated with specific  
214 drug resistance and d) the site confirmed that the data from source document  
215 matched the data captured electronically.

216

### 217 **Performance Analysis**

218 Clinical performance of MTB/XDR test was evaluated using the following outcome  
219 measures: 1) the positive percentage agreement (PPA) and negative percentage  
220 agreement (NPA) for *M. tuberculosis* detection against G4 or Ultra, 2) sensitivity and  
221 specificity for *M. tuberculosis* detection using MGIT culture as the reference  
222 standard; and 3) sensitivity and specificity compared to pDST (for FLQ, the final  
223 result was generated considering all drugs tested for this evaluation) and sequencing  
224 as reference standard independently and in combination as a composite reference  
225 for resistance detection of INH, ETH, FLQs and SLID. The composite reference test  
226 results were categorized as “Resistant” if either pDST or Sequencing results were  
227 “Resistant”; “Susceptible” if both pDST and sequencing were “Susceptible”. Analysis  
228 was performed using RStudio Team (2020) (RStudio: Integrated Development for R.  
229 RStudio, PBC, Boston, MA) and the 95% confidence intervals were determined  
230 using the Wilson score methods.

231

232 We also assessed the ability of the MTB/XDR test to: 1) identify low levels of  
233 resistance to INH and FLQ (MXF) based on the detection of resistance causing  
234 mutations which typically result in borderline minimal inhibitory concentration (MIC)  
235 values that are close to the breakpoint drug concentration used in phenotypic  
236 resistance testing; 2) identify resistance to KAN only, KAN and AMI, or cross-



237 resistance to all three SLID and, 3) identify non-determinate rates. Non-determinate  
238 test results were excluded from the performance analysis.

239

240

241

## 242 **Results**

### 243 **Specimen characteristics**

244 A total of 324 specimens were eligible for inclusion, of these 2 were excluded due to  
245 insufficient specimen volume (Figure 1). The final data analysis was done on 322  
246 specimens which comprised of 46.0% females, 50.3% males and 3.7% of the  
247 specimens with unknown sex (Table 1). Additionally, the median age was 37 years  
248 (13 – 85) among individuals who had specimens included (Table 1). As shown in  
249 Table 1, a positive MGIT culture result was obtained in 92.2% (297/322) of  
250 specimens with 74.4% smear positive. A total of 100 specimens were tested on the  
251 G4 test, 86.0% (86/100) were MTB positive and 74.4% (64/86) of these were RIF  
252 resistant (Table 1, Figure 1). Additionally, 222 specimens were tested on the Ultra  
253 test, with a positive result obtained for 91.9% (204/222) of which 30.4% (62/204)  
254 were RIF resistant, 68.6% (140/204) RIF sensitive and 1% (2/204) RIF indeterminate  
255 (Table 1, Figure 1). An MTB Trace detected result was obtained in 1.8% (4/222) of  
256 specimens tested on the Ultra test (Table 1, Figure 1). Overall, 8.7% (28/322) of the  
257 specimens were negative by the G4 and Ultra tests (Table 1, Figure 1).

258

### 259 **Diagnostic performance of MTB/XDR test for the detection of *M. tuberculosis***

260 The sensitivity of the MTB/XDR test for the detection of *M. tuberculosis* in smear  
261 positive, smear negative and overall was 99.5% (95%CI: 97.5 - 99.9), 94.7%  
262 (95%CI:87.2 - 97.9) and 98.3% (95%CI: 96.1, 99.3). The specificity was 100% (95%  
263 CI: 86.7 – 100) (Table 2).

264

265 The PPA and NPA for MTB/XDR in *M. tuberculosis* detection relative to the G4 test  
266 were 98.8% (95%CI: 93.7-99.8) and 100.0% (95%CI: 78.5-100.0), respectively  
267 (Table 2). In this instance, the MTB/XDR test failed to detect one sample, with a  
268 scant microscopy grading, identified as positive (i.e. MTB detected) by the G4 test.  
269 Similarly, the PPA and NPA for MTB/XDR in *M. tuberculosis* detection relative to the  
270 Ultra test was 99.5% (95%CI: 97.3-99.9) and 100.0% (95%CI: 78.5-100.0),



271 respectively (Table 2). A smear negative sample identified as MTB Trace Detected  
272 by the Ultra test was not detected by the MTB/XDR test.

273

274

275

### 276 **Non-determinate rate**

277 The initial non-determinate rate (ND) observed for the MTB/XDR test was 3.1%  
278 (10/322) (Data not shown). Of these 0.6% were due to “No Result” and 2.5% due to  
279 “Error” results obtained by the MTB/XDR test. Repeat testing of these specimens  
280 rendered a valid result with final ND rate of 0% (Data not shown).

281

### 282 **Diagnostic performance of the MTB/XDR test for drug resistance prediction**

283 The diagnostic performance of the MTB/XDR test against pDST, sequencing and the  
284 composite reference test for all drugs are shown in Figure 2, 3 and 4, respectively.

285

### 286 **Isoniazid & Ethionamide**

287 Results for the test and reference standard for INH were available for 291 samples.  
288 The sensitivity and specificity to detect INH resistance compared to pDST was  
289 90.7% (95% CI: 84.8 – 94.5) and 98.7% (95% CI: 95.3 - 99.6), respectively (Figure  
290 2) while compared to WGS was 98.5% (95% CI: 94.6 – 99.6) and specificity of  
291 99.4% (95% CI: 96.6 – 99.9) respectively (Figure 3). Using a composite reference,  
292 the sensitivity was 90.1% (95% CI: 84.1 – 94.0) and a specificity of 99.3% (95% CI:  
293 96.3 – 99.9) (Figure 4).

294

295 The prediction of low level of INH resistance using sequencing as reference test was  
296 100% (Supplementary Table 2). The majority (95.8%; 23/24) of samples with low  
297 level INH resistance detected harbored the C-15T mutation in the *inhA* promoter and  
298 4.2% (1/24) samples showed the T-8A mutation in the *inhA* promoter  
299 (Supplementary Table 2).

300

301 Ethionamide (ETH) resistance prediction on the MTB/XDR test is based on detection  
302 of mutations in the *inhA* promoter. The sensitivity and specificity in detecting ETH  
303 resistance using pDST as the reference was 64.7% (95% CI: 55.6 – 72.8) and 98.2%  
304 (95%CI: 93.8 – 99.5) respectively (Figure 2). Using WGS and limited to analysis of

305 the *inhA* promoter only the sensitivity was 97.6% (95% CI: 91.6 – 99.3) (Figure 3).  
306 Using the composite reference, the sensitivity was 65.9% (95% CI: 57.1 – 73.6) and  
307 specificity of 100% (Figure 3; Figure 4).

308

309

### 310 **Fluoroquinolones (FLQs)**

311 A total of 231 samples had available results for both the test and pDST for FLQ and  
312 the sensitivity was 90.6% (95% CI: 81.0 – 95.6) (Figure 2). A total of 289 samples  
313 had available results for both the test and WGS and the sensitivity was 95.1% (95%  
314 CI: 86.5 – 98.3) (Figure 3). Using a composite reference, the sensitivity was 90.6%  
315 (95% CI: 81.0 – 95.6) (Figure 4). The specificity was 100% against pDST, WGS and  
316 the composite reference (Figure 2, Figure 3, Figure 4).

317

318 The ability of the MTB/XDR test to accurately predict low level of FLQ resistance  
319 using sequencing as the reference test was 100% (Supplementary Table 3). The  
320 distribution of these *gyrA* mutations were Ala90Val (66.7%; 10/15), Asp94Ala (20%;  
321 3/15) and Ser91Pro (13.3%; 2/15) (Supplementary Table 3).

322

### 323 **Second-line Injectable drugs (AMK, KAN, CAP)**

324 A total of 228 samples had available results for both MTB/XDR and AMK pDST while  
325 it was lower for KAN (n=166) and CAP (n=167). The sensitivity in detecting  
326 resistance to AMK, KAN and CAP using pDST as the reference were 96.2% (95%CI:  
327 87.0 – 98.9); 84.6% (95%CI: 66.5 – 99.3) and 84.0 (95%CI: 65.3 - 93.6), respectively  
328 (Figure 2). The respective sensitivities were higher using WGS as the reference:  
329 98.0% (95%CI: 89.7 - 99.7) for AMK, 98.1% (95%CI: 89.9 - 99.7) for KAN and  
330 98.0% (95%CI: 89.5 - 99.7) for CAP (Figure 3). Using the composite reference, the  
331 sensitivity was 96.2% (95%CI: 87.0 – 98.9) for AMK, 92.7% (95%CI: 82.7 – 97.1) for  
332 KAN and 92.5% (95% CI:82.1 – 97.0) for CAP (Figure 4). All SLIDs had a specificity  
333 of 100% for pDST, sequencing and the composite reference test.

334

335 The ability of the MTB/XDR test to accurately predict resistance to the different  
336 SLIDs were 100% for each of the anti-TB drugs, with cross-resistance between the  
337 SLIDs predicted by the A1401G mutation in the *rrs* gene (Data not shown).  
338 Additionally, resistance to KAN only was predicted by the C-12T mutation in the *eis*

339 promoter with resistance to both KAN and AMK predicted by the C-14T mutation in  
340 the *eis* promoter (Data not shown).

341

342

343

#### 344 **Discrepant result resolution**

345 A total of 74 discrepant results were identified between the MTB/XDR test and  
346 pDST, with 70 false negative and 4 false positive results identified across all drugs  
347 tested (Figure 2).

348

349 Four out of four (100%) of the false positive results were resolved by WGS that  
350 identified mutations predicting INH and ETH resistance, indicating that the initial  
351 susceptible pDST result for both INH and ETH were incorrect.

352

353 Sixty-four out of seventy false negative results (91.4%) were resolved by WGS that  
354 showed the absence of target gene mutations predicting resistance to INH, FLQ,  
355 SLIDs and ETH, indicating that the initial resistant pDST result obtained for the drug  
356 targets were likely incorrect in these specimens. The false negative results in six  
357 specimens (8.6%) were not resolved by WGS, and the cause of the discrepancy was  
358 further investigated. One specimen that was identified as INH resistant by pDST, but  
359 INH susceptible by the MTB/XDR test, showed the presence of a Leu203Leu *fabG1*  
360 mutation that was not identified by the MTB/XDR test. Three specimens that were  
361 identified as FLQ resistant by pDST, but FLQ susceptible by the MTB/XDR test  
362 showed the presence of a Asp94Gly (n=2) and Ala90Val mutation (n=1) in the *gyrA*  
363 gene. One specimen that was identified as KAN, AMK and CAP resistant by pDST,  
364 but susceptible by MTB/XDR showed the presence of a A1401G mutation in the *rrs*  
365 gene. Further investigation confirmed heteroresistance, however, the *rrs* mutant melt  
366 peak was below the detection threshold of the MTB/XDR test and therefore reported  
367 as KAN, AMK and CAP susceptible. Lastly, one specimen identified by the  
368 MTB/XDR test as ETH susceptible, but resistant by pDST, had a G-17T mutation in  
369 the *inhA* promoter region, which was initially missed by the MTB/XDR test.

370

371 A total of 11 discrepant results were identified between the MTB/XDR test and  
372 sequencing, with 10 false negative results and 1 false positive result identified

373 (Figure 3). One false positive result was identified with the MTB/XDR test reporting  
374 an INH resistant result and sequencing showing an INH susceptible result, although  
375 this specimen showed a C-52A mutation in the *ahpC* region, which was not  
376 considered associated with INH resistance by the study site.

377  
378 Out of the 10 false negative results, one specimen was identified as INH susceptible  
379 by MTB/XDR test but had a *fabG1* mutation identified by sequencing. Further  
380 investigation failed to identify a root cause of the discrepancy, thereby indicating that  
381 the MTB/XDR test incorrectly reported this specimen as INH susceptible. The  
382 second specimen was incorrectly processed, and no INH resistance causing  
383 mutation was identified upon resequencing. Three specimens, identified by the  
384 MTB/XDR test as FLQ susceptible, was identified as FLQ resistant by sequencing  
385 with the detection of Asp94Gly (n=2) and both Asp94Gly and Asp94Asn (n=1)  
386 mutations in the *gyrA* gene. The *gyrA* double mutation of Asp94Gly and Asp94Asn  
387 was below the detection threshold of the MTB/XDR test due to hetero-resistant  
388 populations and was therefore not identified as FLQ resistance by the test. AMK,  
389 KAN and CAP resistance was not detected by the MTB/XDR test in one specimen  
390 since the A1401G *rrs* mutant peak was below the detection threshold of the test.  
391 Lastly, ETH resistance was not detected by the MTB/XDR test in one specimen due  
392 to a mixed culture and in a second specimen due to a specimen swop that showed  
393 no *inhA* promoter mutation upon re-sequencing.

394

## 395 **Discussion**

396

397 The demonstrated diagnostic performance of the MTB/XDR test for *M. tuberculosis*  
398 detection met the overall sensitivity ( $\geq 80\%$ ) and specificity ( $\geq 98\%$ ) requirements  
399 relative to culture as outlined in the guidance for next-generation DST by the WHO  
400 (16), with a 98.3% sensitivity and specificity of 100% specificity observed in the  
401 current study. The diagnostic performance of the MTB/XDR test was comparable to  
402 Ultra (pooled sensitivity 90.9% (95%CI: 86.2 – 94.7)); pooled specificity 95.6%  
403 (95%CI: 93.0 – 97.4)) and G4 test (pooled sensitivity of 84.7% (78.6 – 89.9)) and  
404 pooled specificity of 98.4% (95%CI: 97.0 – 99.3) as previously described (17). This  
405 was also seen in the current study with high levels of agreement between the  
406 MTB/XDR and the G4 and Ultra. This can be attributed to the similar limit of

407 detection (LoD) of the MTB/XDR (71.9 CFU/mL (95%CI: 58 to 100)) compared to the  
408 G4 (86.9 CFU/mL (95%CI (72 to 110)) (10). The LoD of Ultra (15.6 CFU/mL),  
409 however, is lower than that of MTB/XDR (11). Interestingly, the diagnostic sensitivity  
410 of the MTB/XDR test in culture positive, smear negative specimens (94.7%) was  
411 better than in Ultra (pooled sensitivity of 77.5% (95%CI: 67.6 to 85.6)) and G4  
412 (pooled sensitivity of 60.6% (95%CI: 48.4 to 71.7)) as previously described (17). This  
413 indicates that although the MTB/XDR test is a reflex test to be used in *M.*  
414 *tuberculosis* positive cases (excluding 'Trace'), its ability to accurately detect *M.*  
415 *tuberculosis* in sputum specimens is on par with Ultra and G4. Further studies on  
416 processing specimens with MTB 'Trace' detected by Ultra which are expected to be  
417 lower than the LoD of MTB/XDR and are for reflex testing is required. The MTB/XDR  
418 test was able to successfully detect more than 98% of MTB samples detected by the  
419 G4 (98.8%) and ULTRA (99.5%) tests, with each comparator test failing to detect  
420 one sample each. These were both smear negative and in the case of ULTRA a  
421 trace result. These finding are supportive of using the MTB/XDR test as a reflex  
422 using the MTB/RIF tests as an indicator for the follow-on testing.

423

424 The clinical performance of the MTB/XDR test performance demonstrated by the  
425 current study is similar to previous studies (18, 19) with sensitivity of >84% observed  
426 for INH, SLIDs and FLQ relative to pDST. The sensitivity for predicting resistance to  
427 INH, FLQ and AMK also met the minimum requirement of the target product profile  
428 for next-generation pDST (sensitivity of >90% for INH, FLQ and sensitivity of ≥80%  
429 for AMK) as specified by the WHO (9, 16). In contrast, lower sensitivity of the MTB  
430 XDR test in predicting ETH resistance (sensitivity of 64.7% (95%CI: 55.6 – 72.8))  
431 compared to pDST was demonstrated in the current study, with sensitivity estimates  
432 comparable to previously published studies (18, 19). This is due to the inclusion of  
433 only the *inhA* promoter target as a proxy for ETH resistance in the MTB/XDR test,  
434 since mutations in additional targets (e.g. *ethA*) have been identified to confer  
435 resistance to ETH in clinical specimen from TB patients (20, 21).

436

437 When considering sequencing alone, the clinical performance of the MTB/XDR  
438 assay for all drug targets increased to >95% sensitivity and >99% specificity (Figure  
439 3). The lowest sensitivity was observed for FLQ (95.1%) due to the presence of  
440 heteroresistant *gyrA* populations in each of these isolates which were below the limit

441 of detection in the clinical specimen. Similarly, the A1401G (*rrs*) mutation was  
442 identified but at a level below detection of the MTB/XDR assay. The overall  
443 sensitivities showed a slight decrease for most drugs and an expected significant  
444 decrease for ETH with specificities remaining at >99% against the composite  
445 reference standard (Figure 4). Sensitivities of >90% were observed for INH and  
446 FLQ, >92% for KAN and CAP, and >96% for AMK which meet the minimum criteria  
447 for the target product profile for next generation DST assays. The lower sensitivity of  
448 65.9% (95%CI: 57.1-73.6) observed for ETH compared to 97.6% relative to  
449 sequencing, was suggestive of the presence of additional mutations in targets not  
450 covered by the assay or false ETH resistance on phenotypic DST. The latter cannot  
451 be confirmed since pDST was not performed for discordant results, however ETH  
452 pDST is known to be unreliable (22). Based on these findings ETH resistance can  
453 be ruled in and not ruled out using the MTB/XDR assay, in agreement with previous  
454 observations (23).

455

456 Overall, the sensitivities observed for the composite reference were comparable to  
457 those previously reported in a geographically diverse setting for INH (90.1% vs  
458 94.0%) and FLQ (90.6% vs 94%) and higher for AMK (96.2% vs 73.0%), KAN  
459 (92.7% vs 86.0%), CAP (92.5% vs 61.0%) and ETH (65.9% vs 54.0%) (23). The  
460 improved sensitivities highlight the accuracy of the assay in predicting resistance,  
461 particularly for INH, FLQ, AMK, KAN and CAP, in our setting. The higher  
462 performance observed when using sequencing as a reference is due to evaluation of  
463 the regions targeted by the assay only and not considering all resistance conferring  
464 mutations across the genome. Further, due to the restricted analysis for sequencing,  
465 the discordance observed between phenotypic susceptibility testing and the  
466 MTB/XDR test could not be resolved.

467

468 The performance of the Xpert XDR in our study for INH resistance detection relative  
469 to pDST was similar to the GenoType MTBDRplus 90.7% (95% CI: 84.8 – 94.5) vs  
470 93% (95% CI: 90 – 95) for INH, however, sensitivity for FLQ resistance detection  
471 was lower than the GenoType MTBDRsl 90.6% (95%CI: 81.0 – 95.6) vs 95%  
472 (95%CI: 91 - 97) (ref 20). When considering performance relative to sequencing,  
473 resistance detection by Xpert XDR for INH was superior to the GenoType



474 MTBDRplus 98.5% (95%CI: 94.6 – 99.6) and equivalent to GenoType MTBDRsl for  
475 FLQ 95.1 (95%CI: 86.5 – 98.3).

476

477 Two shorter standardized regimens for DR-TB are currently recommended by WHO:  
478 a regimen for MDR/RR-TB where the injectable agent has been replaced by BDQ  
479 (used for 6 months), in combination with levofloxacin (LFX)/moxifloxacin (MXF),  
480 ethionamide (ETH), EMB, high-dose INH, PZA and CFZ for 4 months in the  
481 intensive phase; and a 6-month regimen for that includes the new anti-TB agent, Pa,  
482 which was also recommended by WHO in 2020 for use under operational research  
483 conditions, in combination with BDQ and LZD (24). LPAs have been recommended  
484 by the WHO for the detection of *Mycobacterium tuberculosis* (*M. tuberculosis*) strains  
485 resistant to rifampicin, in both smear positive and smear negative sputum specimens  
486 (25, 26). Currently, these LPAs are being used at-scale in South Africa, however,  
487 delayed result reporting is a common problem experienced with routine use mainly  
488 due to technical aspects such as sample batching. Another challenge with LPAs is  
489 its poor sensitivity on smear negative specimens that require repeat testing on  
490 cultured isolates. In a recent study, done at two sites in South Africa the median time  
491 to LPA results ranged between 5.4 – 23.1 days (27). These delays negatively impact  
492 TB control, allowing for the continued transmission of drug resistant *M. tuberculosis*. The test is  
493 capable of determining level of resistance for both INH and FLQ based on the  
494 interpretation of melt-curves detecting the presence of associated mutations. This  
495 allows for supporting clinical management by making available the use of both high-  
496 dose INH and MFX for patient management, particularly patients requiring a salvage  
497 regimen. *tuberculosis* strains and result in inadequate management of patients.  
498 Alternative assays providing the same information are still not readily available. Next-  
499 generation sequencing-based technologies show early promise, however, none have  
500 matured sufficiently to an end-to-end *in vitro* diagnostic assay ready for routine use.

501

502 The NHLS is a key partner of the National TB Program and adapts to having the  
503 latest and most sensitive diagnostic capability to further strengthen the program.  
504 South Africa was the first country to implement the GeneXpert MTB/RIF and  
505 GeneXpert MTB/RIF Ultra assay, at scale, as a smear microscopy replacement  
506 technology in 2011 and one of the first to perform susceptibility testing for new and  
507 repurposed anti-TB drugs (Bedaquiline and Linezolid) as part of diagnosis. Further



508 diagnosis was improved, particularly in HIV co-infected TB-disease individuals,  
509 through replacement of GeneXpert MTB/RIF assay with the Xpert MTB/RIF Ultra  
510 assay in 2017 with South Africa again taking the lead. These efforts have aided in  
511 improved management of people diagnosed with TB and drug-resistant TB, thereby  
512 reducing South Africa's burden of disease.

513

514 NHLS has fully implemented this technology following of the WHO recommendation  
515 to strengthen the detection and management of drug-resistant TB, an emerging  
516 global threat. The deployment of the assay leverages the existing instrument network  
517 and testing capacity, increases utilization and thereby maximizes efficiency. The  
518 potential benefits are a reduction in public health expenditure, a reduction in the  
519 number of repeat tests (through the traditional testing modalities) and a significantly  
520 improved turnaround time. Ultimately, turnaround time improvements benefit those  
521 individuals' requiring treatment by enabling clinicians to take earlier appropriate  
522 management decisions impacting treatment outcomes.

523

524

## 525 **ACKNOWLEDGEMENTS**

526

527 We thank the study investigators, clinical research coordinators, and laboratory staff  
528 at the Centre for Tuberculosis, NICD/NHLS for their diligent efforts.


529 The study sponsor (Cepheid) provided the investigational product, funding and  
530 administrative and logistical support to this study site. The sponsor was involved in  
531 the design, conduct and execution of the clinical study, and assisted in monitoring  
532 and collection of data. The sponsor participated in the interpretation of the data and  
533 preparation of the manuscript. GL and XL are Cepheid employees.

534 SVO, LJ, FI, DN, TG, MvdM collected the data and performed the experiments. XL  
535 performed the statistical analysis. SVO and GL drafted the manuscript. All authors  
536 reviewed and critiqued the draft manuscript and approved the final manuscript prior  
537 to submission for publication.

538

539

540 **Tables & Figures**



541

542

543 **Figure 1.** Flowchart illustrating the diagnostic characteristics of the sediments.

544 MTB/RIF POSITIVE constitutes MTB Detected; MTB/RIF Ultra POSITIVE constitutes MTB Detected Very Low,  
545 MTB Detected Low, MTB Detected Medium, MTB Detected High; MTB/RIF Ultra TRACE constitutes MTB Trace  
546 Detected; MTB/RIF or MTB/RIF Ultra NEGATIVE constitutes MTB Not Detected; RIF RES indicates Rifampicin  
547 Resistant, RIF SENS indicates Rifampicin Sensitive, RIF IND indicates Rifampicin Indeterminate.

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563 **Table 1:** Demographics and diagnostic characteristics of specimens included in the analysis

	<b>Overall (N=322)</b>
<b>Demographic Characteristics</b>	
<b>Sex</b>	
Female	148 (46.0%)
Male	162 (50.3%)
N/A	12 (3.7%)
<b>Age (Years)</b>	
Median [Min, Max]	37 (13-85)
<b>MGIT culture / AFB smear</b>	
% Culture positive [n/N]	92.2% [297/322]
% smear positive [n/N]	74.4% [221/297]
% smear negative [n/N]	25.6% [76/297]
% Culture negative [n/N]	7.8% [25/322]
<b>G4</b>	
%G4 results [n/N]	31.1% [100/322]
% Positive <sup>a</sup> [n/N]	86.0% [86/100]
% RIF RES <sup>d</sup> [n/N]	74.4% [64/86]
% RIF SENS <sup>e</sup> [n/N]	25.6% [22/86]
% Negative <sup>c</sup> [n/N]	14.0% [14/100]
<b>Ultra</b>	
% Ultra results [n/N]	68.9% [222/322]
% Positive <sup>b</sup> [n/N]	91.9% [204/222]
% RIF RES <sup>e</sup> [n/N]	30.4% [62/204]
% RIF SENS <sup>f</sup> [n/N]	68.6% [140/204]
% RIF IND <sup>g</sup> [n/N]	1.0% [2/204]
%Trace <sup>d</sup> [n/N]	1.8% [4/222]
RIF IND <sup>g</sup> [n/N]	100% [4/4]
% Negative <sup>c</sup> [n/N]	6.3% [14/222]

564 <sup>a</sup>G4 Positive constitutes MTB Detected

565 <sup>b</sup>Ultra Positive constitutes MTB Detected Very Low, MTB Detected Low, MTB Detected Medium, MTB Detected High

567 <sup>c</sup>G4 or Ultra Negative constitutes MTB Not Detected

568 <sup>d</sup>Ultra Trace constitutes MTB Trace Detected

569 <sup>e</sup>RIF RES indicates Rifampicin Resistant

570 <sup>f</sup>RIF SENS indicates Rifampicin Sensitive

571 <sup>g</sup>RIF IND indicates Rifampicin Indeterminate

572

573

574


575 **Table 2:** Performance summary of the MTB/XDR test relative to MGIT culture, G4 and Ultra test for  
576 *M. tuberculosis* detection.

	Sensitivity/PPA (95% CI)	Specificity/NPA (95% CI)
<b>MGIT Culture<sup>a</sup></b>		
Overall	98.3% (96.1 – 99.3)	100% (86.7 – 100)
Culture positive, Smear positive	99.5% (97.5 – 99.9)	N/A
Culture positive, Smear negative	94.7% (87.2 – 97.9)	N/A
<b>G4<sup>b</sup></b>	98.8% (95%CI: 93.7-99.8)	100.0% (95%CI: 78.5-100.0)
<b>Ultra<sup>b</sup></b>	99.5% (95%CI: 97.3-99.9)	100.0% (95%CI: 78.5-100.0)

577 <sup>a</sup> Diagnostic Performance of MTB/XDR test in *M. tuberculosis* detection relative to MGIT culture was assessed by  
578 sensitivity and specificity.


579 <sup>b</sup> Diagnostic performance of MTB/XDR test in *M. tuberculosis* detection relative to G4 and Ultra was assessed by  
580 PPA and NPA.

581  
582




583 **Figure 2:** Performance of the MTB/XDR test in predicting resistance to INH, FLQ, AMK, KAN, CAP,  
584 ETH relative to pDST. TP -True Positive, FN – False Negative; TN – True Negative; FP – False  
585 Positive; Sens. – Sensitivity; Spec.- Specificity  
586

587  
588



589 **Figure 3:** Performance of the MTB/XDR test in detection of resistance to INH, FLQ, AMK, KAN, CAP,  
590 ETH relative to sequencing. TP -True Positive, FN – False Negative; TN – True Negative; FP – False  
591 Positive; Sens. – Sensitivity; Spec.- Specificity  
592

593



594

595

**Figure 4:** Performance of the MTB/XDR test in detection of resistance to INH, FLQ, AMK, KAN, CAP, ETH relative to the composite test. TP -True Positive, FN – False Negative; TN – True Negative; FP – False Positive; Sens. – Sensitivity; Spec.- Specificity

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635 **SUPPLEMENTARY DATA**

636

637 **Supplementary Table 1:** Performance of MTB/XDR test compared to MGIT Culture stratified by

638 smear status

		Culture				
		Positive			Negative	Total
		Smear +	Smear -	Overall Culture +	Overall Culture -	
<b>MTB/XDR Test</b>	MTB Detected	220	72	292	0	292
	MTB Not Detected	1	4	5	25	30
	Total	221	76	297	25	322
<b>Performance in Culture Positive Smear Positive group:</b> Sensitivity: 99.5% (220/221), 95% CI: 97.5, 99.9 <b>Performance in Culture Positive Smear Negative group:</b> Sensitivity: 94.7% (72/76), 95% CI: 87.2, 97.9 <b>Performance Overall:</b> Sensitivity: 98.3% (292/297), 95% CI: 96.1, 99.3 Specificity: 100% (25/25), 95% CI: 86.7, 100						

639

640

641 **Supplementary Table 2:** Low Level INH resistance prediction by MTB/XDR test relative to *inhA*

642 promoter mutations identified by sequencing

	INH		Total
	C-15T ( <i>inhA</i> promoter)	T-8C ( <i>inhA</i> promoter)	
Low Level INH Resistance Detected by MTB/XDR test	23	1	24
Total	23 (95.8%)	1 (4.2%)	24 (100%)

643

644 **Supplementary Table 3:** Low level FLQ resistance prediction by MTB/XDR test relative to *gyrA*

645 mutations identified by sequencing

	FLQ			Total
	Ala90Val ( <i>gyrA</i> )	Asp94Ala ( <i>gyrA</i> )	Ser91Pro ( <i>gyrA</i> )	
Low Level FLQ Resistance Detected by MTB/XDR test	10	3	2	15
Total	10 (66.7%)	3 (20.0%)	2 (13.3%)	15 (100.0%)

646

647 **References:**

648

649 1. World Health Organization. 2023. Global tuberculosis report 2023. Geneva:  
650 World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO. World  
651 Health Organization.

652 2. Pai M, Dewan PK, Swaminathan S. 2023. Transforming tuberculosis  
653 diagnosis. Nat Microbiol 8:756–759.

654 3. World Health Organization. 2021. Global tuberculosis report 2021. Geneva:  
655 World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. World  
656 Health Organization.

657 4. World Health Organization. 2022. Global tuberculosis report 2022. Geneva:  
658 World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. World  
659 Health Organization.

660 5. World Health Organization. 2022. Implementing the end TB strategy: the  
661 essentials, 2022 update. Geneva: World Health Organization; 2022. Licence:  
662 CC BY-NC-SA 3.0 IGO. World Health Organization.

663 6. WHO. 2021. WHO consolidated guidelines on tuberculosis. Module 3:  
664 diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva:  
665 World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. World  
666 Health Organization.

667 7. Iruedo J, O'Mahony D, Mabunda S, Wright G, Cawe B. 2017. The effect of  
668 the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural



- 669 setting: a cohort study in South Africa's Eastern Cape Province. BMC Infect  
670 Dis 17:91.
- 671 8. Naidoo P, Toit E, Dunbar R, Lombard C, Caldwell J, Detjen A. 2014. A  
672 Comparison of Multidrug-Resistant Tuberculosis Treatment Commencement  
673 Times in MDRTBPlus Line Probe Assay and Xpert MTB/RIF-Based  
674 Algorithms in a Routine Operational Setting in Cape Town. PLoS ONE.
- 675 9. World Health Organization. 2014. Meeting report: High-priority target product  
676 profiles for new tuberculosis diagnostics: report of a consensus meeting;  
677 World Health Organization (2014). (WHO/HTM/TB/2014.18). World Health  
678 Organization.
- 679 10. Cao Y, Parmar H, Gaur RL, Lieu D, Raghunath S, Via N, Battaglia S, Cirillo  
680 DM, Denkinger C, Georghiou S, Kwiatkowski R, Persing D, Alland D,  
681 Chakravorty S. 2020. Xpert MTB/XDR: A ten-color reflex assay suitable for  
682 point of care settings to detect isoniazid-, fluoroquinolone-, and second line  
683 injectable drug-resistance directly from *Mycobacterium tuberculosis* positive  
684 sputum. BioRxiv <https://doi.org/10.1101/2020.09.08.288787>.
- 685 11. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada  
686 PP, Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG,  
687 Nabeta P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM,  
688 Davidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D.  
689 2017. The New Xpert MTB/RIF Ultra: Improving Detection of *Mycobacterium*  
690 tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-  
691 Care Testing. MBio 8.

- 692 12. Global Laboratory Initiative. 2014. Mycobacteriology Laboratory Manual. First  
693 Edition, April 2014. Stop TB Partnership.
- 694 13. Rüsç-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. 2006.  
695 Multicenter laboratory validation of the BACTEC MGIT 960 technique for  
696 testing susceptibilities of Mycobacterium tuberculosis to classical second-line  
697 drugs and newer antimicrobials. J Clin Microbiol 44:688–692.
- 698 14. World Health Organization. 2018. Technical Report on critical concentrations  
699 for drug susceptibility testing of medicines used in the treatment of drug-  
700 resistant tuberculosis. Geneva: World Health Organization; 2018  
701 (WHO/CDS/TB/2018.5). Licence: CC BY-NC-SA 3.0 IGO. . World Health  
702 Orgaization.
- 703 15. Ismail NA, Ismail F, Joseph L, Govender N, Blows L, Kaniga K, Omar SV.  
704 2020. Epidemiological cut-offs for Sensititre susceptibility testing of  
705 Mycobacterium tuberculosis: interpretive criteria cross validated with whole  
706 genome sequencing. Sci Rep 10:1013.
- 707 16. World Health Organization. 2021. Target product profile for next-generation  
708 drug-susceptibility testing at peripheral centres. Geneva: World Health  
709 Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. World Health  
710 Organization.
- 711 17. Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG,  
712 Ochodo EA, Haraka F, Zwerling AA, Pai M, Steingart KR, Horne DJ. 2021.  
713 Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin

- 714 resistance in adults with presumptive pulmonary tuberculosis. Cochrane  
715 Database Syst Rev 2:CD009593.
- 716 18. Truden S, Sodja E, Žolnir-Dovč M. 2023. Drug-Resistant Tuberculosis on the  
717 Balkan Peninsula: Determination of Drug Resistance Mechanisms with Xpert  
718 MTB/XDR and Whole-Genome Sequencing Analysis. *Microbiol Spectr*  
719 11:e0276122.
- 720 19. Katamba A, Ssengooba W, Sserubiri J, Semugenze D, William KG, Abdunoor  
721 N, Byaruhanga R, Turyahabwe S, Joloba ML. 2023. Evaluation of Xpert ®  
722 MTB/XDR test for susceptibility testing of *Mycobacterium tuberculosis* to first  
723 and second-line drugs in Uganda. medRxiv  
724 <https://doi.org/10.1101/2023.04.03.23288099>.
- 725 20. Vilchèze C, Jacobs WR. 2014. Resistance to Isoniazid and Ethionamide in  
726 *Mycobacterium tuberculosis*: Genes, Mutations, and Causalities. *Microbiol*  
727 *Spectr* 2.
- 728 21. World Health Organization. 2021. Catalogue of mutations in *Mycobacterium*  
729 *tuberculosis* complex and their associatoin with drug resistance. Geneva:  
730 World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. World  
731 Health Organization.
- 732 22. Varma-Basil M, Prasad R. 2015. Dilemmas with ethionamide susceptibility  
733 testing of *Mycobacterium tuberculosis*: A microbiologist & physician's  
734 nightmare. *Indian J Med Res* 142:512–514.

- 735 23. Penn-Nicholson A, Georghiou SB, Ciobanu N, Kazi M, Bhalla M, David A,  
736 Conradie F, Ruhwald M, Crudu V, Rodrigues C, Myneedu VP, Scott L,  
737 Denkinger CM, Schumacher SG, Xpert XDR Trial Consortium. 2021. Clinical  
738 evaluation of the Xpert MTB/XDR assay for rapid detection of isoniazid,  
739 fluoroquinolone, ethionamide and second-line drug resistance: A cross-  
740 sectional multicentre diagnostic accuracy study. medRxiv  
741 <https://doi.org/10.1101/2021.05.06.21256505>.
- 742 24. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N,  
743 Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D,  
744 Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A,  
745 Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel  
746 CM, Spigelman M, ZeNix Trial Team. 2022. Bedaquiline-Pretomanid-Linezolid  
747 Regimens for Drug-Resistant Tuberculosis. *N Engl J Med* 387:810–823.
- 748 25. World Health Organization. 2016. The use of molecular line probe assay for  
749 the detection of resistance to isoniazid and rifampicin: policy update. World  
750 Health Organization.
- 751 26. World Health Organization. 2016. The use of molecular line probe assays for  
752 the detection of resistance to second-line anti-tuberculosis drugs. Policy  
753 guidance . World Health Organization.
- 754 27. Centner C, Dolby T, Hayes C, Zemanay W, Brown P, Munir R, David A, Rieß  
755 F, Nicol M, Brink A, Tagliani E, Cirillo D, Ruhwald M, Scott L, Cox H, Penn-  
756 Nicholson A. 2022. Reflex commercial second-line genotypic susceptibility  
757 testing of residual rifampicin-resistant sputum specimens: a two-site

758 diagnostic laboratory-based feasibility study in South Africa. 4d. Molecular  
759 diagnostics (including POCT and syndromic testing). P1078. ECCMID.  
760